Advances in Screening and Development of Therapeutic Aptamers Against Cancer Cells

被引：18

作者：

Li, Zheng ^{[1
]}

Fu, Xuekun ^{[1
]}

Huang, Jie ^{[1
]}

Zeng, Peiyuan ^{[2
]}

Huang, Yuhong ^{[1
]}

Chen, Xinxin ^{[1
]}

Liang, Chao ^{[1
]}

机构：

[1] Southern Univ Sci & Technol, Dept Biol, Shenzhen, Peoples R China

[2] Univ Victoria, Dept Biochem, Victoria, BC, Canada

来源：

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2021年 / 9卷

关键词：

aptamer; cancer cells; targeted therapy; SELEX; clinical application; DNA APTAMER; RNA APTAMER; PHASE-I; TARGET; EXPRESSION; LIGANDS; AS1411; HEPARANASE; PERIOSTIN; DIAGNOSIS;

D O I：

10.3389/fcell.2021.662791

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Cancer has become the leading cause of death in recent years. As great advances in medical treatment, emerging therapies of various cancers have been developed. Current treatments include surgery, radiotherapy, chemotherapy, immunotherapy, and targeted therapy. Aptamers are synthetic ssDNA or RNA. They can bind tightly to target molecules due to their unique tertiary structure. It is easy for aptamers to be screened, synthesized, programmed, and chemically modified. Aptamers are emerging targeted drugs that hold great potentials, called therapeutic aptamers. There are few types of therapeutic aptamers that have already been approved by the US Food and Drug Administration (FDA) for disease treatment. Now more and more therapeutic aptamers are in the stage of preclinical research or clinical trials. This review summarized the screening and development of therapeutic aptamers against different types of cancer cells.

引用

页数：10

共 104 条

[21] A SIMPLE METHOD FOR GENERATING SINGLE-STRANDED-DNA PROBES LABELED TO HIGH ACTIVITIES [J].

ESPELUND, M ;

STACY, RAP ;

JAKOBSEN, KS .

NUCLEIC ACIDS RESEARCH, 1990, 18 (20) :6157-6158

[22] Thrombin binding aptamer analogues containing inversion of polarity sites endowed with antiproliferative and anti-motility properties against Calu-6 cells [J].

Esposito, Veronica ;

Russo, Annapina ;

Vellecco, Valentina ;

Bucci, Mariarosaria ;

Russo, Giulia ;

Mayol, Luciano ;

Virgilio, Antonella ;

Galeone, Aldo .

BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2018, 1862 (12) :2645-2650

[23]

Frohnmeyer E, 2019, ANALYST, V144, P1840, DOI [10.1039/c8an01616j, 10.1039/C8AN01616J]

[24] Characterization of MNK1b DNA Aptamers That Inhibit Proliferation in MDA-MB231 Breast Cancer Cells [J].

Garcia-Recio, Eva M. ;

Pinto-Diez, Celia ;

Isabel Perez-Morgado, M. ;

Garcia-Hernandez, Marta ;

Fernandez, Geronimo ;

Elena Martin, M. ;

Gonzalez, Victor M. .

MOLECULAR THERAPY-NUCLEIC ACIDS, 2016, 5 :e275

[25] Embracing proteins: structural themes in aptamer-protein complexes [J].

Gelinas, Amy D. ;

Davies, Douglas R. ;

Janjic, Nebojsa .

CURRENT OPINION IN STRUCTURAL BIOLOGY, 2016, 36 :122-132

[26] Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer [J].

Gijs, Marlies ;

Penner, Gregory ;

Blackler, Garth B. ;

Impens, Nathalie R. E. N. ;

Baatout, Sarah ;

Luxen, Andre ;

Aerts, An M. .

PHARMACEUTICALS, 2016, 9 (02)

[27] Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer [J].

Gray, Bethany Powell ;

Kelly, Linsley ;

Ahrens, Douglas P. ;

Barry, Ashley P. ;

Kratschmer, Christina ;

Levy, Matthew ;

Sullenger, Bruce A. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (18) :4761-4766

[28] The emerging field of RNA nanotechnology [J].

Guo, Peixuan .

NATURE NANOTECHNOLOGY, 2010, 5 (12) :833-842

[29] New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy [J].

Haberkorn, Uwe ;

Eder, Matthias ;

Kopka, Klaus ;

Babich, John W. ;

Eisenhut, Michael .

CLINICAL CANCER RESEARCH, 2016, 22 (01) :9-15

[30] Eukaryotic core promoters and the functional basis of transcription initiation [J].

Haberle, Vanja ;

Stark, Alexander .

NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2018, 19 (10) :621-637

← 1 2 3 4 5 6 7 8 9 10 →